Eli Lilly and Co
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 220
- Registration Number
- NCT06400472
- Locations
- ๐ช๐ธ
Hospital Clinico Universitario de Valencia, Valencia, Spain
๐บ๐ธHonor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธSouth Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan, United States
A First-In-Human Study of LY3985297 in Healthy Participants
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT06395012
- Locations
- ๐บ๐ธ
CenExel ACT, Anaheim, California, United States
๐บ๐ธICON, Salt Lake City, Utah, United States
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10000
- Registration Number
- NCT06383390
- Locations
- ๐บ๐ธ
AMZERN Clinical Trial Organization, Peoria, Arizona, United States
๐บ๐ธPhoenix Clinical LLC, Phoenix, Arizona, United States
๐บ๐ธClinical Research Institute of Arizona (CRI) - Sun City West, Sun City West, Arizona, United States
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- ๐บ๐ธ
Hassman Research Institute Marlton Site, Marlton, New Jersey, United States
๐บ๐ธCTI Clinical Research Center, Cincinnati, Ohio, United States
๐บ๐ธVelocity Clinical Research, Gardena, Gardena, California, United States
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 112
- Registration Number
- NCT06370715
- Locations
- ๐ฎ๐ณ
Rajasthan University of Health Sciences, Jaipur, Rajasthan, India
๐ฎ๐ณS. P. Medical College & A G Hospital, Bikaner, Rajasthan, India
๐ฎ๐ณOsmania Medical College & Hospital, Hyderabad, Telangana, India
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06370728
- Locations
- ๐บ๐ธ
ICON Early Phase Services, San Antonio, Texas, United States
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 22
- Registration Number
- NCT06362265
- Locations
- ๐บ๐ธ
University of South Florida, Tampa, Florida, United States
๐บ๐ธHonor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธChildren's Hospital Los Angeles, Los Angeles, California, United States
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT06354660
- Locations
- ๐บ๐ธ
Eastside Research Associates, Redmond, Washington, United States
๐บ๐ธCotton O'Neil Clinical Research Center, Topeka, Kansas, United States
๐บ๐ธPrime Revival Research Institute, LLC, Flower Mound, Texas, United States
A Study of LY3841136 in Overweight and Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 96
- Registration Number
- NCT06345066
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06342596
- Locations
- ๐ฌ๐ง
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom